Skip to main content
Premium Trial:

Request an Annual Quote

CRISPR Firm Intellia Prices IPO at $16 to $18 Per Share

NEW YORK (GenomeWeb) – Intellia Therapeutics has priced shares for its upcoming initial public offering in the range of $16 to $18, according to an amendment to its preliminary prospectus filed today with the US Securities and Exchange Commission.

The Cambridge, Massachusetts-based CRISPR/Cas9 gene-editing firm also announced in the amended prospectus that it will offer 5 million shares of common stock in the IPO, and that the Novartis Institutes for Biomedical Research has agreed to concurrently purchase $5 million in common stock in a separate private placement at a price equal to the offering price.

Intellia had previously announced that Regeneron Pharmaceuticals would purchase $50 million in stock in a similar private placement.

The share pricing places a $90 million ceiling on the offering, though the company is also making 750,000 shares available to the IPO underwriters which would bring the total value to no more than $103.5 million.

Intellia filed is preliminary prospectus with the SEC on April 9.

According to that filing, the firm had $75.8 million in cash and cash equivalents and $66.9 million in working capital as of Dec. 31, 2015.

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.